The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes

You may not qualify if:

• Presence of type 1 diabetes mellitus (defined as C-peptide \<1 ng /ml, \<35y and prone to ketoacidosis)
• Treatment with rapid-acting or short-acting insulin within the last 3 months
• Proliferative retinopathy or maculopathy requiring acute treatment
• Impaired renal function , defined as serum creatinine ≥ 125 µmol/L (≥1.4 mg/dL) for males and ≥ 110 µmol/L (≥1.24 mg/dL) for females
• Impaired liver function, defined as aspartate transaminase (AST) or alanine transaminase (ALT), ≥ 2.5 times the upper limit of normal
• Presence of clinically significant peripheral or autonomic neuropathy that is clearly of non-diabetic origin
• Uncontrolled treated/untreated hypertension (systolic blood pressure (BP) ≥180 or diastolic blood pressure (BP) ≥100 at screening)
• Subjects known to be Hepatitis B surface antigen or Hepatitis C antibody positive with active hepatitis.
• Active infection (e.g., human immunodeficiency virus (HIV), hepatitis), or a history of severe infection during the 30 days prior to screening
• Evidence of immunocompromised status, including but not limited to individuals who have undergone organ transplantation, who are known to be HIV positive, or who are taking immunosuppressive drugs or chronic systemic corticosteroid treatment.
• Major surgical procedure during the 30 days prior to screening
• Diagnosis and/or treatment of malignancy (except for basal cell or squamous cell skin cancer, in-situ carcinoma of the cervix, or in-situ prostate cancer) within the past 5 years
• Known clinically significant gastric emptying abnormality (e.g. severe gastroparesis), or history of gastric bypass (bariatric) surgery
• Thyroid stimulating hormone (TSH) outside of normal limits at screening, or presence of a thyroid nodule detected on physical examination that has not been fully evaluated
• Thyroid hormone therapy that has not been stable for ≥6 weeks prior to Screening
• +13 more criteria